Janus Henderson Group
VIRX

Janus Henderson Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Janus Henderson Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-249,686
Closed -$2M – 2599
2021
Q3 		$2M Sell
249,686
-63,885
-20% -$630K ﹤0.01% 1254
2021
Q2 		$3.55M Sell
313,571
-333,249
-52% -$3.34M ﹤0.01% 1133
2021
Q1 		$5.99M Buy
+646,820
New +$6.74M ﹤0.01% 981

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Janus Henderson Group's VIRX Position: Q4 2021 in Review

Janus Henderson Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 249,686 shares — an estimated $2M sold.

Janus Henderson Group first reported a position in VIRX in Q1 2021 and held it in 3 quarters. The position peaked at $5.99M in Q1 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • Janus Henderson Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Janus Henderson Group sold 249,686 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2M.
  • Janus Henderson Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Janus Henderson Group's Viracta Therapeutics, Inc. Common Stock position peaked at $5.99M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Janus Henderson Group's 13F filing for Q4 2021, filed 14 Feb 2022.